Oridonin alleviates hyperbilirubinemia through activating LXRα-UGT1A1 axis.

[1]  L. Zhai,et al.  Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB. , 2021, International immunopharmacology.

[2]  Kutty Selva Nandakumar,et al.  Design, Synthesis, and Structure-Activity Relationship of N-Aryl-N'-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy. , 2021, Journal of medicinal chemistry.

[3]  Zhongqiu Liu,et al.  UGT1A1 dysfunction increases liver burden and aggravates hepatocyte damage caused by long-term bilirubin metabolism disorder. , 2021, Biochemical pharmacology.

[4]  Dianlei Liu,et al.  Oridonin interferes with simple steatosis of liver cells by regulating autophagy. , 2021, Tissue & Cell.

[5]  H. Ota,et al.  Neonatal wearable device for colorimetry-based real-time detection of jaundice with simultaneous sensing of vitals , 2021, Science Advances.

[6]  Bo Wei,et al.  Hepatoprotective effects of oridonin against bisphenol A induced liver injury in rats via inhibiting the activity of xanthione oxidase. , 2021, The Science of the total environment.

[7]  Shuwen Liu,et al.  Oridonin alleviates d‐GalN/LPS‐induced acute liver injury by inhibiting NLRP3 inflammasome , 2020, Drug development research.

[8]  Qiu-yue Liu,et al.  Regulation of cytochrome P450 4F11 expression by liver X receptor alpha. , 2020, International immunopharmacology.

[9]  Zhanghua Wu,et al.  The roles of liver X receptor α in inflammation and inflammation‐associated diseases , 2020, Journal of cellular physiology.

[10]  R. Tukey,et al.  Differential Role of Liver X Receptor (LXR) α and LXRβ in the Regulation of UDP-Glucuronosyltransferase 1A1 in Humanized UGT1 Mice , 2020, Drug Metabolism and Disposition.

[11]  Baojian Wu,et al.  Circadian Clock Gene Bmal1 Regulates Bilirubin Detoxification: A Potential Mechanism of Feedback Control of Hyperbilirubinemia , 2019, Theranostics.

[12]  Yihan Wu,et al.  Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects. , 2019, Pharmacological research.

[13]  Yu Zhao,et al.  Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  D. Brenner,et al.  The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma , 2019, International journal of molecular sciences.

[15]  X. Tian,et al.  Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities. , 2018, Mini reviews in medicinal chemistry.

[16]  Xueqing Xu,et al.  Functional Characterization of a Novel Lipopolysaccharide-Binding Antimicrobial and Anti-Inflammatory Peptide in Vitro and in Vivo. , 2018, Journal of medicinal chemistry.

[17]  Huijun Sun,et al.  Ginsenoside Rg1 protects against acetaminophen-induced liver injury via activating Nrf2 signaling pathway in vivo and in vitro. , 2018, Regulatory toxicology and pharmacology : RTP.

[18]  S. Zhong,et al.  Gender Differences in the Hepatotoxicity and Toxicokinetics of Emodin: The Potential Mechanisms Mediated by UGT2B7 and MRP2. , 2018, Molecular pharmaceutics.

[19]  L. Huminiecki,et al.  Ethnopharmacological Approaches for Therapy of Jaundice: Part I , 2017, Front. Pharmacol..

[20]  Aaron Saguil,et al.  Evaluation of Jaundice in Adults. , 2017, American family physician.

[21]  Chi-Tang Ho,et al.  Simultaneous characterization and quantification of 17 main compounds in Rabdosia rubescens by high performance liquid chromatography , 2016, Journal of food and drug analysis.

[22]  Shijie Cao,et al.  Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway. , 2016, International journal of oncology.

[23]  W. Figg,et al.  UGT genotyping in belinostat dosing. , 2016, Pharmacological research.

[24]  S. Zhong,et al.  Relation of Transcriptional Factors to the Expression and Activity of Cytochrome P450 and UDP-Glucuronosyltransferases 1A in Human Liver: Co-Expression Network Analysis , 2016, The AAPS Journal.

[25]  Shuwen Liu,et al.  Time-Dependent Metabolism of Luteolin by Human UDP-Glucuronosyltransferases and Its Intestinal First-Pass Glucuronidation in Mice. , 2015, Journal of agricultural and food chemistry.

[26]  Liang Liu,et al.  Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients , 2015, PloS one.

[27]  P. Bosma,et al.  Gene Replacement Therapy for Genetic Hepatocellular Jaundice , 2015, Clinical Reviews in Allergy & Immunology.

[28]  Xiaofu Wang,et al.  Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis. , 2014, The Journal of surgical research.

[29]  Cheng Huang.  Natural modulators of liver X receptors. , 2014, Journal of integrative medicine.

[30]  Nirmal Singh,et al.  Liver X receptors: emerging therapeutic targets for Alzheimer's disease. , 2013, Pharmacological research.

[31]  M. Brady,et al.  PCB 126 and Other Dioxin-Like PCBs Specifically Suppress Hepatic PEPCK Expression via the Aryl Hydrocarbon Receptor , 2012, PloS one.

[32]  T. Ikejima,et al.  Autophagy enhanced phagocytosis of apoptotic cells by oridonin-treated human histocytic lymphoma U937 cells. , 2012, Archives of biochemistry and biophysics.

[33]  Ke Wang,et al.  Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. , 2011, International journal of oncology.

[34]  S. Bhattacharya,et al.  Carlinoside reduces hepatic bilirubin accumulation by stimulating bilirubin-UGT activity through Nrf2 gene expression. , 2011, Biochemical pharmacology.

[35]  C. Thiemermann,et al.  LIVER X RECEPTOR AGONIST GW3965 DOSE-DEPENDENTLY REGULATES LPS-MEDIATED LIVER INJURY AND MODULATES POSTTRANSCRIPTIONAL TNF-&agr; PRODUCTION AND P38 MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION IN LIVER MACROPHAGES , 2009, Shock.

[36]  R. Tukey,et al.  The liver X‐receptor alpha controls hepatic expression of the human bile acid–glucuronidating UGT1A3 enzyme in human cells and transgenic mice , 2006, Hepatology.

[37]  V. Bhutani,et al.  Hyperbilirubinemia and kernicterus. , 2006, Clinics in perinatology.

[38]  S. Foster,et al.  ACTIVATION OF THE LIVER X RECEPTOR PROTECTS AGAINST HEPATIC INJURY IN ENDOTOXEMIA BY SUPPRESSING KUPFFER CELL ACTIVATION , 2006, Shock.

[39]  S. Poloyac,et al.  Dual role of orphan nuclear receptor pregnane X receptor in bilirubin detoxification in mice , 2005, Hepatology.

[40]  I. Abe,et al.  The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. , 2004, Biochemical pharmacology.

[41]  D. Moore,et al.  Induction of bilirubin clearance by the constitutive androstane receptor (CAR) , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Timothy M Willson,et al.  Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. , 2002, Journal of medicinal chemistry.